NASDAQ: ISPCIspecimen Inc Stock
$5.62+0.39 (+7.46%)
Updated May 1, 2026
ISPC Price
$5.62
Fair Value Price
-$2.53
Market Cap
$4.17M
52 Week Low
$4.02
52 Week High
$127.20
P/E
-0.06x
P/B
1.35x
P/S
0.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.93M
Earnings
-$10.49M
Gross Margin
1.2%
Operating Margin
-543.58%
Profit Margin
-543.7%
Debt to Equity
2.09
Operating Cash Flow
-$4M
Beta
0.89
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ISPC Overview
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide through its iSpecimen Market placplatform. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen was incorporated in 2009 and is headquartered in Lexington, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ISPC's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
ISPC
Ranked#40 of 45
Ranked#40 of 45
Be the first to know about important ISPC news, forecast changes, insider trades & much more!
ISPC News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ISPC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ISPC ($5.62) is overvalued by 322.23% relative to our estimate of its Fair Value price of -$2.53 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ISPC ($5.62) is not significantly undervalued (322.23%) relative to our estimate of its Fair Value price of -$2.53 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ISPC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ISPC due diligence checks available for Premium users.
Valuation
ISPC fair value
Fair Value of ISPC stock based on Discounted Cash Flow (DCF)
Price
$5.62
Fair Value
-$2.53
Undervalued by
322.23%
ISPC ($5.62) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ISPC ($5.62) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ISPC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ISPC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.06x
Industry
18.11x
Market
18.83x
ISPC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.35x
Industry
3.56x
ISPC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ISPC's financial health
Profit margin
Revenue
$51.8k
Net Income
-$5.0M
Profit Margin
-9,662.2%
ISPC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ISPC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.5M
Liabilities
$6.4M
Debt to equity
2.09
ISPC's short-term assets ($6.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ISPC's short-term assets ($6.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ISPC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ISPC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$916.9k
Investing
$0.0
Financing
$5.0M
ISPC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ISPC vs Diagnostic & Research Stocks
Ispecimen Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.